According to this piece, ViiV has a new long acting medication in phase 1 research. The piece doesn't go into much detail other than obscurely listed 2 drugs in the new medication. VH184 is list as an integrase inhibitor. VH499 is listed a capsid inhibitor.
At this point, there isn't much more known about the medication. It's aimed to be another long acting medication, usually twice a year. Another biannual med on the market could move these drugs to the forefront of treatment & drive down costs due to competition.
That's all for now, take care.
Cya...
No comments:
Post a Comment